Endoscopic Injection Sclerotherapy Versus N-butyl-2-cyanoacrylate Injection

Sherief Abd-Elsalam113 enrolled

Overview

Endoscopic Injection Sclerotherapy vs N-butyl-2-cyanoacrylate Injection

Endoscopic Injection Sclerotherapy versus N-butyl-2-cyanoacrylate Injection in the Management of Actively Bleeding Esophageal Varices

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

113

Conditions

Bleeding Esophageal Varices

Interventions

Injection SclerotherapyDRUG

5% ethanolamine oleate group

N-butyl-2-cyanoacrylateDRUG

N-butyl-2-cyanoacrylate injection group

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * cirrhotic patients presented with actively bleeding Exclusion Criteria: * other sources of UGIB than esophageal varices, hepatic encephalopathy or hepatocellular carcinoma (HCC)

Locations (1)

Sherief Abd-Elsalam

Tanta, Egypt

Outcomes

Primary Outcomes

Number of patients with controlled bleeding

The Number of patients with controlled bleeding

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.